DUAL labelling ends for most ingredient names on 30 Apr and enters a transition period towards showing only new names on medicine labels, the TGA has reminded.
A small set of ingredient names will continue with dual labelling.
After this date, for most names, labels can show the new ingredient name only, or continue with both names while work is done to change the label, TGA said.
Medicine sponsors have three years to update labels to show only the new name.
For example, labels of medicines containing 'lidocaine (lignocaine)' will need to be updated to show 'lidocaine'.
The transition period for most dual labelled ingredients starts on 01 May and ends on 30 Apr 2026, and from 01 May 2026 medicines must show the sole name, the TGA reported.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Apr 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Apr 23
